Table of Contents
Chapter 1 Ophthalmic Drugs Market: Methodology And Scope
1.1 Market Segmentation and Scope
1.1.1 Segment Scope
1.1.2 Regional Scope
1.1.3 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country Wise Market Estimation Using Bottom Up Approach
1.6.1.3 Approach 3: Country Wise Market Estimation Using Top Down Approach
1.7 List of Secondary Sources
1.8 List of Abbreviations
1.9 Objectives
1.9.1 Objective 1
1.9.2 Objective 2
1.9.3 Objective 3
1.9.4 Objective 4
Chapter 2 Ophthalmic Drugs Market: Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.3 Competitive Insights
Chapter 3 Ophthalmic Drugs Market: Industry Outlook
3.1 Market Lineage Outlook
3.1.1 Parent Market
3.2 Regulatory Framework
3.2.1 Regulatory Bodies, By Region
3.2.2 North America
3.2.3 Europe
3.2.4 Asia Pacific
3.2.5 Latin America
3.2.6 Middle East & Africa
3.3 Patent Expiry Analysis
3.4 Pipeline Analysis
3.4.1 Pipeline Analysis, By Phase (Funder Type- Industry)
3.4.2 Pipeline Analysis, By Phase (Funder Type- All Others)
3.5 Cost Structure Analysis
3.6 Market Dynamics
3.6.1 Market Drivers Analysis
3.6.1.1 Increasing Disease Prevalence
3.6.1.2 Strong Developmental Pipeline
3.6.1.3 Advancements In Drug Delivery
3.6.1.4 Promising Investment Scenario
3.6.2 Market Restraint Analysis
3.6.2.1 Patent Expiry Of Blockbuster Drugs
3.7 Penetration & Growth Prospect Mapping
3.8 Ophthalmic Drugs: Market Analysis Tools
3.8.1 Industry Analysis – Porter’s
3.8.2 Pestle Analysis
3.8.3 Major Deals And Strategic Alliances
3.8.3.1 New Product Launch
3.8.3.2 Acquisition
3.8.3.3 Expansion
3.8.3.4 Partnerships
3.8.3.5 Marketing & Promotions
3.9 Primary Research Analysis
3.9.1 Market Scenario
3.9.2 Key Kol Responses
Chapter 4 Ophthalmic Drugs Market: Segment Analysis, By Drug Class, 2018 – 2030 (USD Million)
4.1 Definition and Scope
4.2 Drug Class Market Share Analysis, 2021 & 2030
4.3 Segment Dashboard
4.4 Global Ophthalmic Drugs Market, by Drug Class, 2018 – 2030 (USD Million)
4.5 Market Size & Forecasts and Trend Analyses, 2018 – 2030 (USD Million)
4.5.1 Antiallergy
4.5.1.1 Antiallergy Market, 2018 – 2030 (USD Million)
4.5.2 Anti-Vegf Agents
4.5.2.1 Anti-Vegf Agents Market, 2018 – 2030 (USD Million)
4.5.3 Anti-Inflammatory
4.5.3.1 Anti-Inflammatory Market, 2018 – 2030 (USD Million)
4.5.3.2 Non-Steroidal Anti-Inflammatory Drugs
4.5.3.2.1 Non-Steroidal Anti-Inflammatory Market, 2018 – 2030 (USD Million)
4.5.3.3 Steroidal Anti-Inflammatory Drugs
4.5.3.3.1 Steroidal Anti-Inflammatory Market, 2018 – 2030 (USD Million)
4.5.4 Antiglaucoma
4.5.4.1 Antiglaucoma Market, 2018 – 2030 (USD Million)
4.5.5 Others
4.5.5.1 Others Market, 2018 – 2030 (USD Million)
Chapter 5 Ophthalmic Drugs Market: Segment Analysis, By Disease, 2018 – 2030 (USD Million)
5.1 Definition and Scope
5.2 Disease Market Share Analysis, 2021 & 2030
5.3 Segment Dashboard
5.4 Global Ophthalmic Drugs Market, by Disease, 2018 – 2030 (USD Million)
5.5 Market Size & Forecasts and Trend Analyses, 2018 – 2030 (USD Million)
5.5.1 Dry Eye
5.5.1.1 Dry Eye Market, 2018 – 2030 (USD Million)
5.5.2 Eye Allergies
5.5.2.1 Eye Allergies Market, 2018 – 2030 (USD Million)
5.5.3 Glaucoma
5.5.3.1 Glaucoma Market, 2018 – 2030 (USD Million)
5.5.4 Eye Infection
5.5.4.1 Eye Infection Market, 2018 – 2030 (USD Million)
5.5.5 Retinal Disorders
5.5.5.1 Retinal Disorders Market, 2018 – 2030 (USD Million)
5.5.5.2 Macular Degeneration
5.5.5.2.1 Macular Degeneration Market, 2018 – 2030 (USD Million)
5.5.5.3 Diabetic Retinopathy
5.5.5.3.1 Diabetic Retinopathy Market, 2018 – 2030 (USD Million)
5.5.5.4 Others
5.5.5.4.1 Others Market, 2018 – 2030 (USD Million)
5.5.6 Uveitis
5.5.6.1 Uveitis Market, 2018 – 2030 (USD Million)
5.5.7 Others
5.5.7.1 Others Market, 2018 – 2030 (USD Million)
Chapter 6 Ophthalmic Drugs Market: Segment Analysis, By Route of Administration, 2018 – 2030 (USD Million)
6.1 Definition and Scope
6.2 Route of Administration Market Share Analysis, 2021 & 2030
6.3 Segment Dashboard
6.4 Global Ophthalmic Drugs Market, by Route of Administration, 2018 – 2030 (USD Million)
6.5 Market Size & Forecasts and Trend Analyses, 2018 – 2030 (USD Million)
6.5.1 Topical
6.5.1.1 Topical Market, 2018 – 2030 (USD Million)
6.5.2 Local Ocular
6.5.2.1 Local Ocular Market, 2018 – 2030 (USD Million)
6.5.2.2 Subconjunctival
6.5.2.2.1 Subconjunctival Market, 2018 – 2030 (USD Million)
6.5.2.3 Intravitreal
6.5.2.3.1 Intravitreal Market, 2018 – 2030 (USD Million)
6.5.2.4 Retrobulbar
6.5.2.4.1 Retrobulbar Market, 2018 – 2030 (USD Million)
6.5.2.5 Intracameral
6.5.2.5.1 Intracameral Market, 2018 – 2030 (USD Million)
6.5.3 Systemic
6.5.3.1 Systemic Market, 2018 – 2030 (USD Million)
Chapter 7 Ophthalmic Drugs Market: Segment Analysis, By Dosage Form, 2018 – 2030 (USD Million)
7.1 Definition and Scope
7.2 Dosage Form Market Share Analysis, 2021 & 2030
7.3 Segment Dashboard
7.4 Global Ophthalmic Drugs Market, by Dosage Form, 2018 – 2030 (USD Million)
7.5 Market Size & Forecasts and Trend Analyses, 2018 – 2030 (USD Million)
7.5.1 Gels
7.5.1.1 Gels Market, 2018 – 2030 (USD Million)
7.5.2 Eye Solutions And Suspensions
7.5.2.1 Eye Solutions And Suspensions Market, 2018 – 2030 (USD Million)
7.5.3 Capsules & Tablets
7.5.3.1 Capsules & Tablets Market, 2018 – 2030 (USD Million)
7.5.4 Eye Drops
7.5.4.1 Eye Drops Market, 2018 – 2030 (USD Million)
7.5.5 Ointments
7.5.5.1 Ointments Market, 2018 – 2030 (USD Million)
Chapter 8 Ophthalmic Drugs Market: Segment Analysis, By Product Type, 2018 – 2030 (USD Million)
8.1 Definition and Scope
8.2 Product Type Market Share Analysis, 2021 & 2030
8.3 Segment Dashboard
8.4 Global Ophthalmic Drugs Market, by Product Type, 2018 – 2030 (USD Million)
8.5 Market Size & Forecasts and Trend Analyses, 2018 – 2030 (USD Million)
8.5.1 Otc Drugs
8.5.1.1 Otc Drugs Market, 2018 – 2030 (USD Million)
8.5.2 Prescription Drugs
8.5.2.1 Prescription Drugs Market, 2018 – 2030 (USD Million)
Chapter 9 Ophthalmic Drugs Market: Segment Analysis, By Region, 2018 – 2030 (USD Million)
9.1 Definition & Scope
9.2 Regional Market Share Analysis, 2021 & 2030
9.3 Regional Market Dashboard
9.4 Regional Market Snapshot
9.5 Regional Market Share and Leading Players, 2021
9.5.1 North America
9.5.2 Europe
9.5.3 Asia Pacific
9.5.4 Latin America
9.5.5 Middle East & Africa
9.6 Swot Analysis
9.6.1 North America
9.6.2 Europe
9.6.3 Asia Pacific
9.6.4 Latin America
9.6.5 Middle East & Africa
9.7 Market Size, & Forecasts, Revenue and Trend Analysis, 2021 – 2030 (USD Million)
9.7.1 North America
9.7.1.1 North America Ophthalmic Drugs Market, 2018-2030 (USD Million)
9.7.1.2 U.S.
9.7.1.2.1 U.S. Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.1.3 Canada
9.7.1.3.1 Canada Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.2 Europe
9.7.2.1 Europe Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.2.2 UK
9.7.2.2.1 UK Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.2.3 Germany
9.7.2.3.1 Germany Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.2.4 France
9.7.2.4.1 France Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.2.5 Italy
9.7.2.5.1 Italy Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.2.6 Spain
9.7.2.6.1 Spain Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.2.7 Russia
9.7.2.7.1 Russia Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.3 Asia PacificC
9.7.3.1 Asia Pacific Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.3.2 Japan
9.7.3.2.1 Japan Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.3.3 China
9.7.3.3.1 China Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.3.4 India
9.7.3.4.1 India Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.3.5 Australia
9.7.3.5.1 Australia Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.3.6 South Korea
9.7.3.6.1 South Korea Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.3.7 Singapore
9.7.3.7.1 Singapore Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.4 Latin America
9.7.4.1 Latin America Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.4.2 Mexico
9.7.4.2.1 Mexico Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.4.3 Brazil
9.7.4.3.1 Brazil Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.4.4 Argentina
9.7.4.4.1 Argentina Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.5 Middle East & Africa
9.7.5.1 Middle East & Africa Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.5.2 South Africa
9.7.5.2.1 South Africa Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.5.3 UAE
9.7.5.3.1 UAE Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.5.4 Saudi Arabia
9.7.5.4.1 Saudi Arabia Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
Chapter 10 Ophthalmic Drugs Market: Competitive Analysis
10.1 Recent Developments & Impact Analysis, by Key Market Participants
10.1.1 Ansoff Matrix
10.1.2 Heat Map Analysis
10.2 Company Categorization
10.2.1 Innovators
10.2.2 Market Leaders
10.3 Vendor Landscape
10.3.1 List Of Key Distributors And Channel Partners
10.3.2 Key Customers
10.3.3 Key Company Market Share Analysis, 2021
10.4 Public Companies
10.4.1 Company Market Position Analysis
10.4.2 Company Market Share, By Region
10.4.3 Competitive Dashboard Analysis
10.4.3.1 Market Differentiators
10.5 Private Companies
10.5.1 List Of Key Emerging Companies
10.5.2 Regional Network Map
10.5.3 Company Market Position Analysis
10.6 Company Profiles
10.6.1 ALCON
10.6.1.1 Company Overview
10.6.1.2 Financial Performance
10.6.1.3 Product Benchmarking
10.6.1.4 Strategic Initiatives
10.6.2 NOVARTIS AG
10.6.2.1 Company Overview
10.6.2.2 Financial Performance
10.6.2.3 Product Benchmarking
10.6.2.4 Strategic Initiatives
10.6.3 JOHNSON & JOHNSON SERVICES, INC.
10.6.3.1 Company Overview
10.6.3.2 Financial Performance
10.6.3.3 Product Benchmarking
10.6.3.4 Strategic Initiatives
10.6.4 BAUSCH HEALTH
10.6.4.1 Company Overview
10.6.4.2 Financial Performance
10.6.4.3 Product Benchmarking
10.6.4.4 Strategic Initiatives
10.6.5 MERCK & CO. INC.
10.6.5.1 Company Overview
10.6.5.2 Financial Performance
10.6.5.3 Product Benchmarking
10.6.5.4 Strategic Initiatives
10.6.6 REGENERON PHARMACEUTICALS, INC.
10.6.6.1 Company Overview
10.6.6.2 Financial Performance
10.6.6.3 Product Benchmarking
10.6.6.4 Strategic Initiatives
10.6.7 COHERUS BIOSCIENCES, INC.
10.6.7.1 Company Overview
10.6.7.2 Financial Performance
10.6.7.3 Product Benchmarking
10.6.7.4 Strategic Initiatives
10.6.8 ALLERGAN
10.6.8.1 Company Overview
10.6.8.2 Financial Performance
10.6.8.3 Product Benchmarking
10.6.8.4 Strategic Initiatives
10.6.9 PFIZER, INC.
10.6.9.1 Company Overview
10.6.9.2 Financial Performance
10.6.9.3 Product Benchmarking
10.6.9.4 Strategic Initiatives
10.6.10 BAYER AG
10.6.10.1 Company Overview
10.6.10.2 Financial Performance
10.6.10.3 Product Benchmarking
10.6.10.4 Strategic Initiatives
10.6.11 SANTEN PHARMACEUTICALS CO. LTD.
10.6.11.1 Company Overview
10.6.11.2 Financial Performance
10.6.11.3 Product Benchmarking
10.6.11.4 Strategic Initiatives
10.6.12 GENETECH, INC.
10.6.12.1 Company Overview
10.6.12.2 Financial Performance
10.6.12.3 Product Benchmarking
10.6.12.4 Strategic Initiatives